EUCLID
2017
Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease
In 13,885 patients with symptomatic peripheral artery disease, ticagrelor monotherapy did not reduce cardiovascular death, myocardial infarction or ischaemic stroke compared with clopidogrel monotherapy.
Result
Efficacy: Composite of CV death, MI or ischaemic strokeHR 1.02 (95% CI 0.92-1.13) · P = 0.65
Below 1 favours ticagrelor monotherapy, above 1 favours clopidogrel monotherapy.
- Absolute difference
- 0.2 points
The absolute difference is derived from the event rates.
Also reported: Acute limb ischaemia and major bleeding 1.7 % and 1.6 % in both arms.
- Subtopic
- Antithrombotic therapy
- Design
- Double-blind, event-driven RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 PAADACC/AHA 2024 PAD
- Source
- Hiatt WR, Fowkes FG, et al. N Engl J Med. 2017;376(1):32-40.doi 10.1056/NEJMoa1611688
Discussion & critique
A clean, fully powered null result with no aspirin arm, so it cannot address antiplatelet choice beyond the two drugs tested. Its value is negative evidence: escalating single-antiplatelet potency buys nothing in PAD, and clopidogrel remains the reference monotherapy.